-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the ‘940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The ‘940 patent, entitled “Manufacturing of Bupivacaine Multivesicular Liposomes” pr ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Company Overview - Pacira BioSciences, Inc. (NASDAQ: PCRX) stock is currently trading at $18, a significant decline from its peak of $115 per share in 2015 and over $75 per share in March 2022 [2]. Stock Performance - The stock has experienced a near-constant decline, reaching a low of approximately $13 in mid-August [2]. Investment Insights - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch for, buy and sell ratings, product sales forecasts, and integrated financial statements [2].

Core Viewpoint - Pacira BioSciences, Inc. reported third-quarter 2024 adjusted earnings of 79 cents per share, exceeding the Zacks Consensus Estimate of 72 cents, while total revenues reached $168.6 million, a 3% year-over-year increase but slightly below the consensus estimate of $169 million [1]. Financial Performance - Adjusted earnings for Q3 2024 were 79 cents per share, up from 72 cents in the same quarter last year [1]. - Total revenues for the quarter were $168.6 million, a 3% increase year over year, but missed the Zacks Consensus Estimate of $169 million [1]. - Exparel's net product sales were $132 million, reflecting a 3% increase from the previous year and surpassing the Zacks Consensus Estimate of $131.2 million [3]. - Zilretta's net product sales were $28.4 million, slightly down year over year and below the Zacks Consensus Estimate of $30.6 million [5]. - Iovera's net product sales were $5.7 million, an 8% increase from the previous year, but also missed the Zacks Consensus Estimate of $5.99 million [5]. - Royalty revenues amounted to $0.9 million, showing significant year-over-year growth [6]. Expenses - Research and development (R&D) expenses (excluding stock-based compensation) were $17.3 million, down 7% from the previous year due to lower product development and regulatory costs [7]. - Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) increased by 10% year over year to $65 million, primarily due to litigation costs and increased investments in commercial and market access organizations [8]. Financial Guidance - The company maintained its 2024 financial guidance, expecting total revenues between $680 million and $705 million [9]. - Adjusted R&D expenses are projected to be between $70 million and $80 million, while adjusted SG&A expenses are expected to range from $245 million to $265 million [9]. - The adjusted gross margin is anticipated to be between 74% and 76% for 2024 [9]. Recent Developments - The Centers for Medicare and Medicaid Services (CMS) proposed a rule for 2025 that includes Exparel among non-opioid treatments eligible for separate Medicare reimbursement, effective January 1, 2025 [10][11]. - A permanent product-specific J-code for Exparel was issued by CMS, set to take effect on January 1, 2025, to improve insurance coverage for the drug [12]. - The company faced a setback when a U.S. District Court ruled that its '495 patent for Exparel is not valid, and it is currently evaluating legal options [13].

Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.72%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.73 per share when it actually produced earnings of $0.89, delivering a surprise of 21.92%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other J ...

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2024 Financial Results -- Conference call today at 4:30 p.m. ET -- PARSIPPANY, NJ, November 6, 2024 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights • Total revenues of $168.6 million • Net product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETT ...

PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing the ...

Pacira BioSciences (PCRX) announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel (bupivacaine liposome injectable suspension), to facilitate better insurance coverage for the drug. This new J-code will take effect on Jan. 1, 2025, replacing the existing C-code (C9290), which has been in use since 2019. Please note that J-codes are reimbursement codes used by insurance companies, including Medicare ...

-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for EXPAREL® (bupivacaine lipos ...